COG-ANBL1221: A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 764038, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma

Print this page

COG-ANBL1221: A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 764038, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma

1. To determine if the addition of a molecularly
targeted anti-cancer agent (temsirolimus or ch14.18) to the chemotherapy backbone of irinotecan and temozolomide will be tolerable and will result in improved response rates in
patients with refractory, relapsed or progressive
neuroblastoma.

2. To identify whether temsirolimus or ch14.18 is the optimal therapeutic agent to consider for
further testing in a future Phase III randomized trial for treatment of newly diagnosed high risk
neuroblastoma.

3. To compare the response rates (RR) for patients receiving temsirolimus or ch14.18 in
combination with irinotecan and temozolomide

4. To compare the progression free survival and overall survival rates for patients
receiving temsirolimus or ch14.18 in combination with irinotecan and temozolomide

5. To compare the toxicities associated with temsirolimus or ch14.18 when combined with
irinotecan and temozolomide in patients with
refractory, relapsed or progressive neuroblastoma

6. To compare the ability to maintain intended dose intensity of all agents when temsirolimus or
ch14.18 is combined with irinotecan and temozolomide in patients with refractory, relapsed or progressive neuroblastoma

7. To determine the concordance between tumor responses as defined by standard International
Neuroblastoma Response Criteria (INRC) versus response per the revised INRC.

8. To study the clinical relevance of naturally occurring anti-glycan antibodies in patients receiving ch14.18 antibody
.
9. To study the clinical relevance of NK receptor NKp30 isoforms in patients receiving ch14.18 antibody or temsirolimus
.

Protocol Number: 111301
Phase: Phase II
Applicable Disease Sites: Any Site
Drugs Involved: TEMSIROLIMUS
IRINOTECAN
TEMOZOLOMIDE
ch14.18
Principal Investigator: Richard Drachtman
Scope: National
Therapies Involved: Chemotherapy multiple agents systemic
Participating Institutions: Rutgers Cancer Institute of New Jersey

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@cinj.rutgers.edu.

precision medicine at Rutgers Cancer Institute

 

Donate Now

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health